



Sophiris Bio Inc.
Investor Relations Department
1258 Prospect Street
La Jolla, CA 92037
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

NASDAQ: SPHS ¹

Last Trade:	2.33
Trade Time:	3:58 PM ET Sep 19, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.80 - 3.48
Volume	N/A
Market Cap. (\$M)	70.277
Shares Out (M)	30.110

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Sophiris Bio Inc. is a late-stage, clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Topsalysin is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Sep 13, 2017

[Sophiris Bio Secures up to \\$10 Million in Term Loans from Silicon Valley Bank](#)

Aug 17, 2017

[Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference](#)

Aug 10, 2017

[Sophiris Bio Reports Second Quarter Financial Results and Key Corporate Highlights](#)

Jun 23, 2017

[Sophiris Bio Added to Russell Microcap Index](#)

Jun 8, 2017

[Sophiris Bio Announces that the First Patient Has Been Dosed in Phase 2b Study of Topsalysin in Patients with Clinically Significant Localized Prostate Cancer](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 27, 2017

[Annual Report \(10-K\)](#)

Apr 13, 2017

[Definitive Proxy Statement](#)

Aug 10, 2017

[Quarterly Report \(10-Q\)](#)

May 15, 2017

[Quarterly Report \(10-Q\)](#)

Nov 9, 2016

[Quarterly Report \(10-Q\)](#)